Consistent with the findings from human HCC, concomitant DLC1 down-regulation and EZH2 up-regulation was observed in these malignancies, suggesting the implications of EZH2 up-regulation in silencing DLC1 expression in different human cancers. This evidence concerns the gene EZH2 and hepatocellular carcinoma.